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The anaphase-promoting complex/cyclo-
some (APC/C) inhibitor Emi1 controls pro-
gression to S phase andmitosis by stabiliz-
ing key APC/C ubiquitination substrates,
including cyclin A. Examining Emi1 binding
proteins, we identified the Evi5 oncogene
as a regulator of Emi1 accumulation. Evi5
antagonizes SCFbTrCP-dependent Emi1
ubiquitination and destruction by binding
to a site adjacent to Emi1’s DSGxxS degron
and blocking both degron phosphorylation
byPolo-like kinases and subsequentbTrCP
binding. Thus,Evi5 functionsasastabilizing
factor maintaining Emi1 levels in S/G2
phase. Evi5 protein accumulates in early
G1 following Plk1 destruction and is de-
graded in a Plk1- and ubiquitin-dependent
manner in early mitosis. Ablation of Evi5 in-
duces precocious degradation of Emi1 by
the Plk/SCFbTrCP pathway, causing prema-
ture APC/C activation; cyclin destruction;
cell-cycle arrest; centrosome overduplica-
tion; and, finally, mitotic catastrophe. We
propose that the balance of Evi5 and Polo-
like kinase activities determines the timely
accumulation of Emi1 and cyclin, ensuring
mitotic fidelity.
INTRODUCTION
Progression through the eukaryotic cell cycle is driven by os-
cillation of the activity of cyclin-dependent kinases (Cdks)
(Murray, 2004). Cdk activity is controlled at many levels,
but critically by regulating the stability of cyclin itself. CyclinsA and B are destroyed in mitosis through their ability to serve
as substrates of the anaphase-promoting complex/cyclo-
some (APC/C), a large multisubunit E3 ubiquitin ligase
(Harper et al., 2002). Like other E3 ubiquitin ligases, the
APC/C selects specific protein substrates and directs the
formation of ubiquitin chains on them, marking them for de-
struction by the 26S proteasome (Jackson et al., 2000).
What is generally less clear is the identity and mechanism
of various accessory factors (Jackson et al., 2000) that reg-
ulate the interaction of E3 enzymes with their targets and
thereby link protein destruction to the physiological state of
the cell.
The APC/C itself is subject to extensive physiological reg-
ulation. Its activation is directed by two positive regulators,
Cdc20 and Cdh1 (Harper et al., 2002). Cdc20 is known to
activate the APC/C during mitosis, whereas Cdh1 activates
the APC/C in late mitosis and G1 (Harper et al., 2002). Full
ubiquitination activity of the APC/C in mitosis requires its di-
rect phosphorylation by the cyclin B/Cdc2 kinase (Kraft et al.,
2003; Harper et al., 2002), as well as the inactivation of sev-
eral inhibitory proteins that restrain APC/C activity. The pro-
teins MAD2 and BubR1 and other components of the spin-
dle-assembly checkpoint inhibit the APC/C in complex with
Cdc20 until all chromosomes are aligned at the metaphase
plate and spindle tension is established, thereby ensuring
that all kinetochores are attached to both poles of the mitotic
spindle (Lew and Burke, 2003). Emi1, originally isolated and
described in our lab, inhibits the APC/C in complex with ei-
ther Cdc20 or Cdh1 and is required to maintain the stability
of APC/C substrates such as cyclins A and B in interphase
(Hsu et al., 2002; Reimann et al., 2001a, 2001b). Specifically,
Emi1 accumulation in late G1 promotes S phase entry by
shutting off APC/CCdh1 activity, thereby driving cyclin A ac-
cumulation (Hsu et al., 2002). In this context, Emi1 is a central
target of the cyclin D/retinoblastoma/E2F pathway because,
even in the absence of E2F activation and with only basal
levels of cyclin A transcription, Emi1 overexpression is suffi-
cient to drive S phase by stabilizing cyclin A protein. Through
its connection to the cyclin D/Rb/E2F pathway, Emi1 pro-
vides a critical link from growth-factor stimulation to the inac-
tivation of the APC/C (first described by Lukas et al., 1999)
and progression to mitosis (Hsu et al., 2002).Cell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc. 367
Figure 1. Evi5 Is a Cell-Cycle-Regulated and Centrosomally Localized Emi1-Interacting Protein
(A) Schematic of human Evi5 protein, its closest human homologs, and a candidate Evi5 ortholog in Drosophila. The relative positions of the amino-terminal
candidate RabGAP domain and carboxy-terminal coiled-coil domain are depicted by red and blue boxes. Mouse and Xenopus Evi5 are almost identical to
human Evi5 in both domain structure and sequence (91% and 86% identity, respectively).
(B) Endogenous Evi5 and Emi1 proteins form a complex in vivo. Equal amounts of 293T whole-cell lysate were subjected to immunoprecipitation assays
using control (normal rabbit IgG) or Evi5 antibodies. Immunoprecipitates were immunoblotted as shown. Asterisk designates crossreactive IgG heavy chain.368 Cell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc.
Emi1 inactivation in prophase is triggered by its ubiquitina-
tion and subsequent degradation by the SCF ubiquitin ligase
in complex with the substrate-specific F box adaptor protein
bTrCP (Guardavaccaro et al., 2003; Margottin-Goguet et al.,
2003). bTrCP binds a DSGxxS consensus motif in its sub-
strates only when both serines in the motif are phosphory-
lated (Fuchs et al., 2004). For Emi1, this phosphorylation
on the DSGxxS site is triggered in prophase by the Polo-
like kinase Plk1 (Hansen et al., 2004; Moshe et al., 2004).
SCFbTrCP is constitutively active in the cell, and thus the
strong activation of Plk1 in mitosis (Golsteyn et al., 1995)
would appear to be a sufficient explanation for why Emi1 is
stable throughout interphase until cells enter prophase.
However, other Polo kinase family members such as
Plk2–4, or even low levels of Plk1, may function earlier in
the cell cycle, suggesting the need for a mechanism to inhibit
Polo-like kinases in interphase (Ang and Harper, 2004).
Although Emi1 functions to stabilize APC/C substrates, lit-
tle is known about the factors that function upstream of the
Emi1 protein to regulate its stability or activity. To better un-
derstand Emi1 regulation of the cell cycle, we examined the
activities of over 25 Emi1-interacting proteins (EIPs) identified
in a well-validated yeast two-hybrid screen for proteins bind-
ing to the N-terminal regulatory domain of Emi1 (Reimann
et al., 2001a). To look for EIPs that act upstream of Emi1,
we undertook a siRNA-based approach to identify factors
required for Emi1 stability in vivo. Here, we describe the iden-
tification and characterization of the Evi5 oncogene as an EIP
required to stabilize the Emi1 protein during interphase. Evi5
was first cloned in mice as a frequent site of retroviral integra-
tion in a model of T cell lymphoma (Liao et al., 1997) and later
as the site of a reciprocal translocation event in a patient with
stage 4S neuroblastoma (Roberts et al., 1998). Though Evi5
contains a conserved amino-terminal Rab GTPase-activat-
ing protein homology and a carboxy-terminal coiled-coil do-
main, little was known about Evi5’s physiological role in the
cell.
We show here that Evi5 acts to stabilize Emi1 during inter-
phase by blocking the ability of Polo-like kinases to trigger
ubiquitin-dependent destruction of Emi1 by the SCFbTrCP
complex. Notably, the cell-cycle-dependent accumulation
of Evi5 itself appears to be largely regulated through its stabil-
ity and by the activity of Plk1. We find that Evi5 accumulation
occurs after Plk1 destruction in G1 and that Evi5 destructionin prophase is triggered by the activation of Plk1. Collectively,
our data indicate that Evi5 serves as a critical regulator of cell-
cycle progression by defining a window of stability for Emi1
during interphase analogous to the window of stability that
Emi1 provides for APC/C substrates over a similar period.
RESULTS
Evi5 Is a Cell-Cycle-Regulated Protein Identified
in a Screen for Emi1 Regulatory Proteins
To define Emi1’s function in cell-cycle regulation, we had
conducted several yeast two-hybrid screens using a Xeno-
pus ovary cDNA library and Emi1 amino and carboxyl termini
as bait to isolate a number of EIPs (Reimann et al., 2001a).
We then screened for EIPs that affected Emi1 accumulation
when inactivated by RNAi (A. Lebre, A.G.E., J.D.R.R., and
P.K.J., unpublished data). One upstream regulator identified
was the Xenopus ortholog of Evi5, a protein conserved from
humans to flies (Figure 1A). Sequence analysis suggests that
Evi5 contains an amino-terminal RabGAP domain (see Fig-
ure S1 in the Supplemental Data available with this article on-
line) and a large carboxy-terminal coiled-coil domain. Be-
cause of the high degree of identity between Xenopus and
human Evi5 (86% identity), we chose to characterize human
Evi5 in subsequent experiments. Evi5 is a member of a family
of homologous proteins exhibiting similar domain structure,
including an uncharacterized ORF we call Evi5 homolog
(Evi5H) and GAPCenA, a centrosomally localized GTPase-
activating protein (GAP) for the Rab6 GTPase (Cuif et al.,
1999) (Figure 1A).
To characterize the human Evi5 protein and verify the
yeast two-hybrid interaction, we produced affinity-purified
rabbit antibodies, which recognized a doublet of species of
100 kDa on immunoblots of HeLa lysate (Figure S2A).
Both species disappeared following blocking of antibody
with antigen (Figure S2A) or treatment of cells with siRNA di-
rected against Evi5 but not GFP (Figure S2B), supporting
their specificity. Three separate siRNAs targeting the Evi5
mRNA gave identical silencing. Reduced-mobility forms of
Evi5 were identified as phosphorylated species by treatment
of cell lysates with l-phosphatase (data not shown). We
found that endogenous Emi1 and Evi5 proteins coprecipitate
from asynchronous lysates (Figure 1B) and purified,(C) Recombinant Evi5 binds recombinant Emi1 in vitro. Binding reactions contained each protein at 1 mM final concentration, and MBP-associated com-
plexes were captured on amylose beads, washed, and eluted with SDS sample buffer. Eluates were analyzed by SDS-PAGE and silver staining to detect
bound GST-Evi5 protein.
(D) Evi5 protein accumulates in early G1 phase, reaches maximal levels by late G1, and decreases in early mitosis concomitantly with Emi1. HeLa cells were
synchronized in mitosis by the nocodazole block-and-release procedure and at the G1/S transition by double-thymidine block followed by release into no-
codazole. Time points were analyzed by immunoblot analysis as above.
(E) Evi5 downregulation in early mitosis requires proteasome activity. HeLa cells were synchronized at the G1/S transition by double-thymidine block fol-
lowed by release into nocodazole. Four hours after release from the second thymidine block, DMSO or the proteasome inhibitor epoxomicin was added to
themedia. Time points were collected as indicated and analyzed by immunoblotting. Lysates were blotted for phosphorylated histone H3 to verify that treat-
ment with proteasome inhibitor did not block mitotic entry.
(F) Evi5 and Emi1 each localize to the interphase centrosome, but Evi5 leaves the centrosome in prophase. Asynchronous U2OS cells were processed for
immunofluorescence analysis using mouse anti-g-tubulin and rabbit anti-Evi5 or anti-Emi1 antibodies. Cells were fixed with methanol to best preserve cen-
trosomal localization of Emi1. Centrosomes are magnified to the right and are shown with (top) or without (bottom) g-tubulin staining to emphasize the pres-
ence or absence of Evi5 or Emi1 at the centrosome. Bars, 5 mm.Cell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc. 369
recombinant Emi1 and Evi5 proteins bind in vitro (Figure 1C),
providing physical evidence for direct Emi1-Evi5 interaction.
We next asked whether Evi5 protein levels oscillate during
the somatic cell cycle. Lysates generated from HeLa cells
synchronized by (1) nocodazole block-and-release or (2)
double-thymidine block-and-release into nocodazole proce-
dures were analyzed by immunoblotting. Evi5 begins to ac-
cumulate in early G1, 6 hr after release from nocodazole, and
reaches maximal levels coincident with the beginning of
Emi1 accumulation and S phase entry (Figure 1D, left). Blot-
ting lysates fromHeLa cells arrested at the G1/S transition by
double-thymidine block and then released into nocodazole
demonstrated that Evi5 levels drop early in mitosis, at
roughly the same time that Emi1 is destroyed (Figure 1D,
right). The downregulation of Evi5 in mitosis requires protea-
some activity because Evi5 was efficiently stabilized in cells
synchronized at the G1/S transition and then released into
nocodazole by addition of the specific proteasome inhibitor
epoxomicin (Figure 1E).
Examining the subcellular localization of Evi5 by immuno-
fluorescence microscopy, we found that interphase U2OS
cells stained with a-Evi5 antibodies showed predominantly
centrosomal staining in 100% of cells, as judged by cos-
taining for g-tubulin (Figure 1F; see also Faitar et al., 2005).
Affinity-purified a-Evi5 antibodies from two other rabbits
gave identical staining patterns (data not shown). Blocking
the antibodies with antigen (Figure S2C) or inactivation of
Evi5 with siRNA (Figure S2D) validated the specificity of
Evi5 staining. Notably, Evi5 was absent from the centrosome
in mitotic cells (Figure 1F), suggesting that the pool of centro-
some-localized Evi5 departs at the same time that the bulk of
Evi5 is destroyed in prophase. We also observed staining of
Emi1 at interphase centrosomes (Figure 1F), in addition to
previous data showing Emi1 in the nucleus (Hsu et al., 2002).
To further test whether Evi5 destruction in prophase re-
quires proteasome-mediated degradation, we showed that
(1) the half-life of Evi5 protein in asynchronous HeLa cells is
increased from 1 hr to 4 hr by addition of the proteasome in-
hibitor MG-132 (Figure S3A), (2) the Evi5 protein is ubiquiti-
nated in vivo (Figures S3B and S3C), and (3) mitotic HeLa
cell extracts can efficiently ubiquitinate Evi5 protein (Figure
S3D). Although Evi5 appears to be destroyed by ubiquitin-
dependent proteolysis in early mitosis in mammalian cell
culture, Evi5 was not degraded in mitotic or Cdh1-supple-
mented interphase Xenopus egg extracts (Figure S3E), was
not ubiquitinated in a standard in vitro APC/C reaction (Fig-
ure S3F), and was not stabilized by expression of the APC/C
inhibitor Emi1 in asynchronous or mitotic cells (Figure S3G).
From these data, we conclude that Evi5 downregulation in
early mitosis occurs through a ubiquitin- and proteasome-
dependent, but APC/C-independent, mechanism.
Evi5 Contains an Amino-Terminal Emi1 Binding
Domain and a Carboxy-Terminal
Centrosomal-Targeting Domain
To locate regions of Evi5 required for binding to Emi1 and lo-
calization of Evi5, we assayed full-length as well as amino-
and carboxy-terminal fragments of Evi5 (Figure 2A) for their370 Cell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc.ability to bind Emi1 and for their localization in vivo. Coimmu-
noprecipitation analysis showed that full-length Evi5 bound
full-length Emi1 and the Emi1 amino terminus but not the
Emi1 carboxyl terminus (Figure 2B, left). Similarly, Emi1
bound the amino terminus of Evi5 efficiently but not the
Evi5 carboxyl terminus (Figure 2B, right), showing that
each protein binds the other through its amino terminus,
consistent with the original yeast two-hybrid data.
As with endogenous Evi5, we found that interphase U2OS
cells expressing myc-tagged Evi5 showed prominent cen-
trosomal staining as judged by costaining for g-tubulin (Fig-
ure 2C). myc-Evi5C showed centrosomal staining, whereas
myc-Evi5N did not.
We conclude that Evi5 contains two functional domains:
an Emi1 binding domain within its N terminus and a centro-
somal-localization domain within its C terminus (summarized
in Figure 2A). We propose that colocalization of Evi5 with
Emi1 at interphase centrosomes may be an important deter-
minant for Evi5’s role in stabilizing Emi1 (see below).
The Polo-like Kinase Plk1 Triggers Evi5 Destruction
in Mitosis
To understand the cell-cycle regulation of Evi5 levels, we
wanted to determine what triggers Evi5 destruction in early
mitosis. Phosphorylation by mitotic kinases, including cyclin
B/Cdc2 and the Polo-like kinases, is instrumental in effecting
critical mitotic transitions. Studies from our lab and others
(Hansen et al., 2004; Moshe et al., 2004) showed that Plk1
triggers mitotic destruction of Emi1, and we suspected that
Evi5 destruction might be coordinately regulated by Plk1.
Immunoblotting of synchronized lysates (identical to those
in Figure 1D) showed that the timing of Plk1 destruction after
mitotic exit corresponds closely to the accumulation of Evi5
in early G1, whereas the activation of Plk1 in early mitosis is
coincident with the timing of Evi5 destruction (Figure 3A).
Moreover, activated Plk1 becomes enriched at centrosomes
in early mitosis at roughly the time when Evi5 disappears
from centrosomes (Figure 3B). This would be consistent
with amodel in which high Plk1 kinase activity is antagonistic
to Evi5 accumulation or, more directly, phosphorylates Evi5
in mitosis to trigger its destruction. To directly test the role of
Plk1 in Evi5 degradation, we immunoblotted lysates gener-
ated from HeLa cells treated with GFP or Plk1 siRNA and
synchronized by double-thymidine block-and-release into
nocodazole (see Figure 2B in Hansen et al., 2004). Although
Plk1 siRNA-treated cells showed a 2 hr delay in mitotic entry
(as judged by Cdc2 tyrosine dephosphorylation and Cdc27
phosphorylation), Evi5 was significantly stabilized in the ab-
sence of Plk1, even at late time points when the Plk1-de-
pleted cells had clearly become mitotic (Figure 3C).
Because Plk1 is required for Evi5 destruction, we asked
whether Evi5 was a direct target of Plk1. Evi5 contains six
consensus sites (D/E-X-S/T) for phosphorylation by Plk1
(Nakajima et al., 2003) (Figure 3D). To test whether Evi5 is
a substrate of Plk1, and to map its phosphorylation sites,
we phosphorylated GST-tagged versions of Evi5 in vitro us-
ing recombinant Xenopus Polo-like kinase (Plx1) (Figure 3E).
Full-length Evi5 was efficiently phosphorylated by Plx1, as
Figure 2. Evi5 Contains an Amino-Terminal Emi1 Binding Domain and a Carboxy-Terminal Targeting Domain
(A) Schematic of full-length human Evi5 protein and fragments used in this study.
(B) Expressed Evi5 binds to Emi1, and each protein binds the other through its amino-terminal domain. Human 293T cells were transfected with expression
vectors as indicated. After 48 hr, lysates were generated and normalized, and equal amounts of lysate were used in each binding assay.
(C) Expressed Evi5 is targeted to the centrosome by its carboxy-terminal coiled-coil domain. U2OS cells were transiently transfected with expression vectors
as indicated for 48 hr, fixed, and stained with anti-myc antibodies. Centrosomes aremagnified to the right and shownwith (top) or without (bottom) g-tubulin
staining to emphasize the presence or absence of Evi5 at the centrosome. Bars, 5 mm.were two individual point mutants in the two amino-terminal
Plk1 sites. Conversely, a small deletion of the carboxy-termi-
nal 76 amino acids (DC76), which removes the other four
candidate Plk1 sites, is a very poor substrate for Plx1 in vitro.
An Evi5 mutant lacking all six Plk1 sites was not more com-
promised in its phosphorylation by Plx1 than the DC76 mu-
tant alone was (data not shown), supporting the hypothesis
that the C-terminal sites are the most likely sites for Plk1
phosphorylation. Finally, a point mutant missing each of
these four carboxy-terminal sites (4Plk1) was also fully de-
ficient inphosphorylationbyPlx1.Coimmunoprecipitationex-
periments show that Evi5 can bind directly to Plk1, even in the
absence of Plk1 kinase activity (Figure S4; see Discussion).
To determine whether phosphorylation by Plk1 in mitosis
is required for Evi5 destruction, we tested the stability of
Evi5 wild-type and Plk1-site mutant proteins in mitosis. Ex-pressed wild-type Evi5 protein was efficiently degraded in
mitotic HeLa cells, whereas Evi5 DC76 and Evi5 4Plk1
were substantially stabilized (Figure 3F). Expression of these
stabilized Evi5 mutants did not fully stabilize the bulk pool of
Emi1 or that of downstream targets of APC/C inhibition by
Emi1, such as cyclin A, in these cells. We suspect this may
be due to the presence of a second mechanism that inacti-
vates Evi5 in mitosis (see Discussion).
Evi5 Regulates the Accumulation of Emi1 and Cyclin
A Proteins in Late G1
To further define the functional relationship between Emi1
and Evi5, we treated cells with siRNA against Evi5 and ex-
amined the effect on Emi1 levels. Depletion of Evi5 protein in
asynchronously growing HeLa cells results in loss of Emi1,
as well as cyclin A and B proteins (Figure S5A). Conversely,Cell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc. 371
Figure 3. Evi5 Degradation in Early Mitosis Requires Phosphorylation by the Polo-like Kinase Plk1
(A) Cell-cycle oscillation of Evi5 protein levels correlates inversely with Plk1 oscillation. Lysates identical to those used in Figure 1D were analyzed by im-
munoblot analysis using Evi5 and Plk1 antibodies.
(B) Evi5 localization at the centrosome correlates inversely with presence of Plk1 at the centrosome. Asynchronous U2OS cells were processed for immu-
nofluorescence using anti-Evi5 and anti-Plk1 antibodies, as well as Hoechst to mark DNA. Bars, 5 mm.
(C) Inactivation of Plk1 by RNA interference stabilizes Evi5 inmitosis. HeLa cells were synchronized by double-thymidine block-and-release into nocodazole.
siRNA treatment was initiated 4 hr after the release from the first thymidine block. Cells were harvested at the indicated times following release from the
second thymidine block, and lysates were generated for immunoblot analysis.
(D) Schematic of candidate Plk1 phosphorylation sites in Evi5. The relative positions of six candidate Plk1 phosphorylation sites (labeled A–F) are shown.
(E) Wild-type Evi5, but not mutants lacking the carboxy-terminal candidate Plk1 sites, is efficiently phosphorylated by Polo-like kinase in vitro. Equal amounts
of recombinant wild-type Evi5 as well as mutants lacking candidate Plk1 sites were each phosphorylated in vitro with recombinant Plx1. Reaction products
were analyzed by SDS-PAGE and autoradiography as well as silver staining to verify equal loading of Evi5 substrate in each reaction. The 4Plk1 point
mutant has slightly increased mobility, both in vivo and in vitro. Careful sequencing of this mutant eliminated the possibility of premature truncation, and we
suspect that its altered mobility is due to deletion of acidic residues within the four Plk1 sites.
(F) Evi5 mutants defective in Plk1 phosphorylation are stabilized in mitosis compared to wild-type protein. Constructs expressing wild-type, DC76, or
4Plk1 versions of Evi5 were transfected into HeLa cells, which were then synchronized in mitosis by treatment with nocodazole. Mitotic cells were har-
vested by shakeoff, and lysates were generated for immunoblotting.372 Cell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc.
treatment of HeLa cells with siRNA directed against Emi1
has little effect on Evi5 accumulation but causes significant
downregulation of cyclins A and B, both known downstream
targets of Emi1 (Figure S5B).
To determine whether the loss of Emi1 and cyclin A in
Evi5-depleted cells occurred at the level of protein stability,
we treated HeLa cells with GFP or Evi5 siRNA and then
synchronized the cells by nocodazole block-and-release.
Whereas cells treated with GFP siRNA exit mitosis and accu-
mulate Emi1 and cyclin A normally, cells treated with Evi5
siRNA fail to accumulate these proteins (Figure 4A). Addition
of proteasome inhibitor 7 hr after nocodazole release rescued
accumulation of both Emi1 and cyclin A (Figure 4A). Thus, the
loss of Emi1 and cyclin A protein in cells depleted of Evi5 likely
occurs predominantly at the level of protein stability (we ex-
clude checkpoint arrest below). A similar, reciprocal experi-
ment showed that the kinetics of Evi5 accumulation is un-
changed in the absence of Emi1, demonstrating that Emi1
is not required to maintain the stability of Evi5 (Figure 4B).
To show that Evi5 knockdown did not cause a failure of cells
to exit the previousmitosis, we examined early time points af-
ter release. We found a slight delay (2 hr) in mitotic exit as
judged by cyclin B degradation and flow cytometry
(Figure S6A), but this kinetic effect was too minor to explain
the dramatic failure to accumulate Emi1 and cyclin A.
Our earlier work demonstrated that cyclin A accumulation
requires inhibition of the APC/C by Emi1 (Hsu et al., 2002).
To determine whether Evi5 regulates cyclin A levels indirectly
through Emi1 stabilization or by another mechanism, we
tested whether we could uncouple cyclin A accumulation
from the requirement for Evi5 by expressing a nondegradable
Emi1 mutant in Evi5-depleted cells. HeLa cells were trans-
fected with either wild-type or nondegradable Emi1 for
24 hr, followed by the Evi5 depletion and synchronization
protocol used in Figure 4A. Expressed wild-type Emi1, like
endogenous Emi1, was unstable in the absence of Evi5 pro-
tein, whereas nondegradable Emi1 lacking the bTrCP de-
gron remained stable (Figure 4C). Thus, Evi5 directly controls
Emi1 protein stability, even when expressed Emi1 is un-
coupled from endogenous transcriptional or translational
controls. These data suggest that the effect of Evi5 ablation
on Emi1 levels is unlikely to arise through secondary effects,
such as cell-cycle perturbations, because the transfected
Emi1 is constitutively expressed from a strong promoter.
Flow cytometry confirmed that HeLa cells depleted of Evi5
by RNAi showed no substantial change in cell-cycle profile
(Figure S11). This result also shows that ablation of Evi5
causes Emi1 degradation by the SCFbTrCP pathway. Sec-
ond, nondegradable Emi1, but not wild-type Emi1, fully res-
cues cyclin A levels in the absence of Evi5 (Figure 4C), sug-
gesting that Evi5’s effect on cyclin A stability occurs indirectly
through Emi1 stabilization. Thus, Evi5 stabilizes Emi1, which
in turn stabilizes cyclin A.
To directly measure the effect of Evi5 depletion on Emi1
protein stability, HeLa cells were arrested in S phase with
uniformly high Emi1 and high Evi5 levels by 21 hr thymidine
treatment. The cells were then transfected with GFP or
Evi5 siRNA in the continued presence of thymidine for anadditional 21 hr, after which the cells were released into fresh
medium containing cycloheximide to inhibit new protein syn-
thesis. The stability of Emi1 protein was reduced in the ab-
sence of Evi5 (Figure 4D), with a reduction in half-life from
3 hr to 1.5 hr, again suggesting that Evi5 functions to stabilize
Emi1 directly at the level of protein stability.
To validate the conclusion that Emi1 instability in the ab-
sence of Evi5 occurs by the known SCFbTrCP- (Margottin-
Goguet et al., 2003) and Plk1-dependent mechanism
(Hansen et al., 2004), we expressed dominant-negative ver-
sions of bTrCP and Polo-like kinases and assayed Emi1
levels following Evi5 depletion by RNA interference. Expres-
sion of dominant-negative bTrCP (bTrCPDF) resulted in sub-
stantial stabilization of cotransfected Emi1, nearly to the
levels seen in control cells (Figure 4E). Similarly, expression
of kinase-defective (kd), dominant-negative versions of
Plk1, 2, and 3 in Evi5-depleted cells rescued Emi1 levels
(Figure 4F), although to varying extents. The Plk2 rescue vec-
tor was most effective, showing a high efficiency of rescue
(compared to Plk3-kd) despite its low level of expression
(compared to Plk1-kd). We suspect that Plk2-kd, unlike
the other Polo-like kinases, rescues efficiently due to its cen-
trosomal localization in interphase (Warnke et al., 2004),
where Evi5 is also localized and appears to stabilize Emi1.
Together, these results support amodel in which Evi5 knock-
down by RNA interference precociously activates Plk- and
SCFbTrCP-dependent destruction of Emi1.
Given the centrosomal localization of Evi5, we considered
the possibility that Emi1 failed to accumulate in cells lacking
Evi5 due to activation of the recently characterized p53-
dependent G1 centrosome checkpoint (Borel et al., 2002).
We consider this unlikely because HeLa cells are functionally
inactive for p53, and direct analysis in matched wild-type or
p53/ HCT116 cells demonstrated that the Evi5 require-
ment for Emi1 and cyclin stability is independent of p53
(Figure S6B).
We also examined whether Evi5 might affect Emi1 and/or
cyclin accumulation by affecting their mRNA levels, which in-
crease in late G1 in response to the E2F transcription factor
(Hsu et al., 2002). Examination of mRNA levels by Northern
blot analysis of synchronized cells showed that Evi5 mRNA
levels do not oscillate in the cell cycle (Figure S7A), in agree-
ment with previously published data (Whitfield et al., 2002).
Although Evi5 siRNA treatment followed by nocodazole
block-and-release does result in a modest change in Emi1
and cyclin A mRNA levels (Figure S7B), this is unlikely to ac-
count for the strong change seen in protein accumulation.
Thus, we conclude that Evi5 primarily directs Emi1 and cyclin
A accumulation through a strong protein stabilization effect.
Evi5 Maintains Emi1 Stability by Blocking Both
Phosphorylation of Emi1 by Polo-like Kinase
and Binding of Phosphorylated Emi1 to SCFbTrCP
We next considered the possibility that Evi5 might stabilize
Emi1 in interphase by shielding Emi1 from phosphorylation
by Plks. We first tested this hypothesis by determining
whether overexpression of Evi5 could block Plk-induced
destruction of Emi1 in vivo. Overexpression of Plk1 efficientlyCell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc. 373
Figure 4. Evi5 Regulates the Stabilization of Emi1 and Cyclin A Proteins in Late G1
(A) Ablation of Evi5 causes failure to accumulate Emi1 and cyclin A proteins in late G1 through a process requiring proteasome activity. HeLa cells were
treated with GFP or Evi5 siRNA at t =22 hr and nocodazole at t =18 and were released into fresh media at t = 0. Seven hours after nocodazole release,
DMSO (above) or proteasome inhibitor MG-132 (below) was added to the media. Time points were collected as indicated and analyzed by immunoblotting.
(B) Emi1 is not required for the accumulation of Evi5 protein in G1. Synchronization of HeLa cells was carried out as in (A), except that cells were treated with
siRNA against Emi1 rather than Evi5.
(C) Overexpression of nondegradable Emi1 rescues cyclin A accumulation in Evi5-depleted cells. HeLa cells were transfected with constructs expressing
myc-tagged wild-type Emi1 or nondegradable (ND) Emi1 (S145A/S149A lacking the DSGxxS motif required for SCFbTrCP binding) for 24 hr and then trans-
fected with siRNA and synchronized with nocodazole as in (A). Cells were harvested 18 hr after release from nocodazole and processed for immunoblot
analysis.
(D) Emi1 protein stability is decreased in the absence of Evi5. HeLa cells were arrested in S phase by a single 21 hr thymidine block and then treated with GFP
or Evi5 siRNA in the continued presence of thymidine for an additional 21 hr. At time zero, cells were released into normal media and cycloheximide was
added to block protein synthesis. Time points were collected, and lysates were analyzed by immunoblotting for Emi1 levels (left) and quantified by densi-
tometry (right).
(E) Downregulation of Emi1 after Evi5 knockdown uses the known bTrCP-dependent pathway for Emi1 destruction. Experiment was as in (C), except that
cells were transfected with empty vector, bTrCP wild-type, or dominant-negative bTrCP DF constructs in addition to the myc-Emi1 reporter construct.
(F) The destruction of Emi1 induced by Evi5 knockdown requires Polo-like kinase activity. Experiment was as in (E), except that cells were transfected with
kinase-defective versions of Plk1, 2, or 3.374 Cell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc.
Figure 5. Evi5 Controls Emi1 Stability by Blocking Phosphorylation of the Emi1 Degron by Polo-like Kinase and Recruitment of
SCFbTrCP to Phosphorylated Emi1
(A) Evi5 overexpression blocks Plk-induced destruction of Emi1 in vivo. 293T cells were cotransfected with myc-Emi1, HA alone, or HA-Plk1, as well as myc
alone or myc-Evi5 constructs. After 48 hr, lysates were generated for immunoblotting.
(B) Emi1 requires residues 210–216 to bind Evi5. 293T cells were cotransfected with HA-Evi5 and myc-Emi1 (wild-type or a series of polyalanine point mu-
tants) for 48 hr. Lysates were generated and normalized, and equal amounts were used in each binding assay.
(C) Evi5 does not block Plk-induced destruction of Emi1 210–216*. Assay was conducted as in (A), except that cells were transfected with either Emi1 wild-
type or 210–216* vectors.
(D) Evi5 blocks destruction of Emi1 in mitotic HeLa cell lysate. In vitro-translated, 35S-labeled Emi1 was incubated with GST or GST-Evi5 protein, then added
to whole-cell lysates generated fromHeLa cells synchronized inmitosis by nocodazole block. Time points were removed as indicated and reaction products
were analyzed by SDS-PAGE and autoradiography.
(E) Evi5 blocks recruitment of bTrCP to Emi1 in vitro. (Above) GST-Emi1-N4 protein was allowed to bind an excess of MBP or MBP-Evi5N protein, and Emi1
bound complexes were captured on glutathione agarose beads, washed, phosphorylated using recombinant Plx1 kinase, and then incubated with in vitro-
translated 35S-labeled bTrCP. Beads were washed and eluted with sample buffer, and eluates were analyzed by SDS-PAGE and autoradiography as well as
Coomassie staining to verify equal amounts of Emi1 substrate on the beads in each reaction. (Below) As above, except that GST-Emi1-N4 was first phos-
phorylated with Plx1 and was then bound to MBP or MBP-Evi5N protein, captured on glutathione agarose beads, and incubated with 35S-labeled bTrCP.
(F) Evi5 blocks phosphorylation of Emi1 by Polo-like kinase in vitro. Experiment was as in (E), except that Emi1-N4 protein was preincubated with MBP or
MBP-Evi5N, captured on beads, and phosphorylated using recombinant Plx1 kinase and [g-32P]ATP. Phosphorylated Emi1 was analyzed by SDS-PAGE
and autoradiography as well as Coomassie staining to verify equal amounts of Emi1 substrate on the beads in each reaction.triggers Emi1 destruction in a proteasome- and SCFbTrCP-
dependent manner (Hansen et al., 2004). Coexpression of
Evi5 rescues Emi1 accumulation almost completely, at least
as well as expression of dominant-negative bTrCP DF (Fig-
ure 5A). Expression of Evi5N, which is itself a poor Plk sub-
strate, rescued Emi1 levels as well, suggesting that the res-
cue phenotype was not merely due to titration of Plk1 kinase
activity but rather required the specific N-terminal Emi1
binding function.
To further demonstrate that rescue of Emi1 stability by
Evi5 was direct, we first isolated an Emi1 mutant that is un-
able to bind Evi5 in vivo and then (see below) tested whether
this Emi1 mutant was resistant to rescue by Evi5. In vitro
binding experiments using deletion fragments of Emi1showed that Evi5 binds a 110 amino acid region of Emi1
(aa 135–244, Emi1-N4) previously shown to contain the crit-
ical phosphodegron for recognition of Emi1 by SCFbTrCP and
to be fully sufficient for bTrCP binding (Margottin-Goguet
et al., 2003) (Figure S8, lanes 1–3). Whereas phosphorylation
of both serines within the DSGxxS degron is required for
Emi1 binding to bTrCP, mutation of these serines had little
effect on binding to Evi5 (Figure S8, lane 4), and prephos-
phorylation of this motif by Plk1 had no effect on Evi5 binding
(data not shown). Thus, Evi5 binds a neighboring but distinct
region of Emi1 from the DSGxxS bound by SCFbTrCP. With
this knowledge, we created point mutants in full-length
Emi1, converting short patches of conserved residues within
the Emi1-N4 region to polyalanine. CoimmunoprecipitationCell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc. 375
analysis showed that mutation of residues 210–216 in Emi1
abrogates binding to Evi5 in vivo (Figure 5B). Whereas Emi1
210–216* is degraded like wild-type Emi1 upon Plk1 overex-
pression, its stability is not rescued by coexpression of Evi5
(Figure 5C). These data support a model in which Evi5 stabi-
lizes Emi1 by directly binding Emi1 and blocking its phos-
phorylation by Plk1.
To further validate this idea, we turned to in vitro systems.
Addition of Evi5 to Emi1 destruction assays carried out in mi-
totic HeLa cell lysate caused substantial stabilization of the
Emi1 substrate (Figure 5D). Incubation of the minimal de-
gron-containing Emi1-N4 fragment with Evi5 caused
a marked decline in Plx1-induced binding of Emi1 to bTrCP,
either when Evi5 was preincubated with Emi1 prior to Emi1’ s
phosphorylation by Plk1 (Figure 5E, top) or when Evi5 was
incubated with prephosphorylated Emi1 (Figure 5E, bottom).
We demonstrated that Evi5 did not bind to bTrCP, excluding
the possibility that Evi5 blocked binding of bTrCP to Emi1 by
binding bTrCP itself (Figure S9). Finally, preincubation of
Emi1 protein with Evi5 resulted in a substantial decrease in
Emi1 phosphorylation by Polo kinase (Figure 5F). These
data suggest that Evi5 binding is capable of stabilizing
Emi1 at two steps: (1) inhibition of phosphorylation by
Polo-like kinases and (2) inhibition of recruitment of bTrCP
to phosphorylated Emi1. We also asked whether Evi5 bound
Emi1 remains capable of inhibiting the APC/C. Indeed, we
found that Emi1 bound to Evi5 in vitro does retain its ability
to bind both Cdc20 and Cdh1, suggesting that Evi5-bound
Emi1 is functional for APC/C inhibition (Figure S10). In sum-
mary, our in vitro studies support the conclusion that Evi5
can bind to determinants surrounding the Plk1 phosphoryla-
tion-regulated Emi1 degron and serves as a stabilizing factor
for Emi1 by blocking precocious triggering of its phosphory-
lation and destruction.
Evi5 Ablation Causes Cell-Cycle Arrest
and Mitotic Abnormalities Due to Increased
Centrosome Number
To determine the biological significance of Evi5 expression,
we asked whether Evi5 was important to sustain growth
and to maintain mitotic and genomic fidelity. Consistent
with our data showing that Evi5 is required for Emi1 and
cyclin A stability, treatment of asynchronous human retinal
pigment epithelial (RPE) cells with Evi5 siRNA resulted in
a substantial decrease in growth rate compared to control
(Figure 6A) and a dramatic drop in mitotic index (from 2.2%
to 0.19%; Figure 6B). Equivalent treatment of U2OS cells
caused a smaller drop in mitotic index (3.1% to 1.5%). Inac-
tivation of Evi5 in HeLa cells did show a substantial decrease
in proliferation (data not shown), consistentwith their failure to
accumulate Emi1 and cyclin, but nonetheless showed no
clear change inmitotic index upon treatmentwith Evi5 siRNA.
Despite their different effects on overall proliferation, RPE and
U2OS cells are similar to HeLa cells in their dependency on
Evi5 to maintain Emi1 and cyclin A stability (data not shown).
Flow cytometry of RPE cells treated with Evi5 siRNA
showed a significant decrease in G2/M fraction compared
to GFP control, whereas equivalent analysis of HeLa and376 Cell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc.U2OS cells showed essentially unchanged cell-cycle profiles
(Figure S11). These flow cytometry data reinforce the argu-
ment that the effect of Evi5 siRNA treatment in HeLa cells
on Emi1 and cyclin A accumulation is a direct result of
knockdown of Evi5 levels rather than an indirect effect
caused by cell-cycle perturbations. We suspect that HeLa
cells fail to show a drop inmitotic index after Evi5 knockdown
because of checkpoint defects or activated oncogene and
cyclin/Cdk activities in this highly transformed cell line. In-
deed, a large percentage of HeLa cells treated with Evi5
siRNA showed spindle aberrancies inmitosis, many showing
increased centrosome and spindle-pole number (Figures 6B
and 6C). The increase in centrosome number likely reflects
a failure to separate centrosomes into daughter cells follow-
ing mitotic catastrophe linked to spindle abnormalities. RPE
and U2OS cells also accumulated spindle aberrancies, but
at a significantly lower frequency (Figure 6B). As is the
case with many other growth-regulatory proteins, we sus-
pect that HeLa cells, which are highly transformed and pro-
liferate more quickly than RPE and U2OS cells, are able to
bypass the need for Evi5 in regulating mitotic entry. At the
same time, the enhanced proliferation rate of HeLa cells
may reveal the requirement for Evi5 in centrosome function,
mitotic control, and ultimately genomic stability. Thus, in tu-
mor cells, misregulation of Evi5 may drive oncogenic pro-
gression by inducing mitotic defects and genome instability.
DISCUSSION
We have identified the Evi5 oncogene as a factor critical for
themaintenance of Emi1 protein stability and cyclin accumu-
lation during interphase. Evi5 protein accumulates in early G1
and is degraded by ubiquitin-dependent proteolysis in early
mitosis in a Plk1-dependent but APC/C-independent man-
ner. Evi5 binding to Emi1 shields Emi1 from phosphorylation
by Polo-like kinases and blocks recruitment of phosphory-
latedEmi1 toSCFbTrCP (see Figure 7 formodel).Misregulation
of Evi5 levels by RNA interference results in cell-cycle arrest
and centrosome-number abnormalities in vivo, suggesting
that Evi5 may not only regulate cyclin accumulation and cell
division but also contribute to timing mechanisms ensuring
mitotic fidelity.
The Period of Evi5 Expression during the Cell Cycle
Defines a Window of Emi1 and Cyclin Stability
Like cyclin A and Emi1, Evi5 accumulates during G1 and is
degraded in early mitosis via ubiquitin-dependent proteoly-
sis. Cyclin A accumulation at the G1/S transition requires
both transcription by the growth-factor-responsive E2F tran-
scription factor and stabilization by Emi1 (Hsu et al., 2002).
Emi1 expression at G1/S also requires E2F (Hsu et al.,
2002), and our studies here suggest that the presence of
Evi5 is also required to stabilize newly transcribed and trans-
lated Emi1. Evi5 accumulation itself appears to be largely in-
dependent of transcription, functioning mainly at the level of
protein stability.
We propose that, following mitotic exit, Plk1 is destroyed
and Evi5 stability is restored. As cyclin D- and cyclin
Figure 6. Evi5 Misregulation Causes Defects in Cell-Cycle Progression, as Well as Mitotic Abnormalities
(A) Evi5 is required to maintain normal growth rates. Human retinal pigment epithelial (RPE) cells were plated at equal density, transfected with GFP or Evi5
siRNA, and harvested at the indicated time points for counting as well as immunoblot analysis to monitor progression of Evi5 knockdown.
(B) Ablation of Evi5 by RNA interference results in a decrease inmitotic index and an uncoupling of the cell cycle from the centrosome duplication cycle. RPE,
U2OS, and HeLa cells were plated onto coverslips, transfected with GFP or Evi5 siRNA, and stained with antibodies against g-tubulin and a-tubulin and
Hoechst to mark DNA. To determine mitotic index, cells were judged to be in mitosis by presence of a mitotic spindle or condensation of DNA. To determine
centrosome number, bodies were classed as centrosomes if they stained positively with g-tubulin and visibly nucleated microtubules by a-tubulin staining.
(C) Ablation of Evi5 by RNA interference results in a high frequency of centrosome abnormalities in HeLa cells. Asynchronous HeLa cells were treated with
GFP or Evi5 siRNA for 48 hr and then processed for immunofluorescence using antibodies against a-tubulin and centrin, as well as Hoechst to mark DNA.
Bars, 5 mm.E-dependent kinases become active and begin to inactivate
Rb and allowE2F activation, the transcription of Emi1 and cy-
clin A follows. In the presence of Evi5, Emi1 accumulates,
causing inactivation of the APC/Candallowing cyclin A accu-
mulation and S phase entry. APC/C inactivation also allows
the stabilization of Skp2 (Ang and Harper, 2004), the F box
adaptor that triggers destruction of p27, thus providing an
additional mechanism to enhance activation of cyclin E-de-
pendent kinase and E2F activation. As cells progress to early
mitosis, the activation of Plk1 triggers the destruction of Evi5
(by an unknown E3) and Emi1 (by SCFbTrCP) and activation of
the APC/C. Because both Emi1 and Evi5 levels are coordi-
nately controlled by phosphorylation by Plk1, we suggest
that Evi5 degradation may be triggered specifically in mitosis
by a mitotically activated ubiquitin ligase. Phosphorylation of
Evi5 by Plk1 in early mitosis could be the critical signal to re-
cruit this ubiquitin ligase. We are currently investigating the
determinants of Evi5 degradation.
While it is clear that Plk1 is important for degradation of
Evi5 in mitosis, the inability of stabilized Evi5 mutants to sta-bilize Emi1 in mitosis suggests that an additional inactivation
step, such as phosphorylation of Emi1 or Evi5, may be suf-
ficient to remove Evi5 and render Emi1 accessible to phos-
phorylation by Plk1 and recognition by SCFbTrCP. Polo-like
kinases are recruited to their substrates via binding to phos-
phorylated motifs in the substrate (Elia et al., 2003). Studies
from our lab have shown that phosphorylation of Emi1 by
Plk1 is strongly enhanced by prior phosphorylation of Emi1
by Cdc2 (Hansen et al., 2004), and our in vivo binding exper-
iments between Evi5 and Plk1 suggest that Plk1 binds spe-
cifically to the phosphorylated form of Evi5 (Figure S4). Thus,
both Emi1 and Evi5 are likely phosphorylated by a mitotically
activated kinase (or kinases) prior to binding to and phos-
phorylation by Plk1. Preliminary data suggest that addition
of cyclin B/Cdc2 to Emi1/Evi5 binding assays blocks their
binding in vitro (A.G.E. and P.K.J., unpublished data). This
is consistent with a model in which phosphorylation of
Emi1, or Evi5, in early mitosis by cyclin B/cdc2 may be a crit-
ical event which coordinately regulates disruption of the Evi5/
Emi1 complex as well as recruitment of Plk1 to theseCell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc. 377
Figure 7. Model
Amodel is shown depicting stabilization of Emi1 by Evi5 at the centrosome in interphase, as well as the steps in the destruction of both proteins. The ability of
Evi5 to stabilize Emi1 may be affected by its association with the centrosome.proteins. Interestingly, preliminary immunofluorescence data
shows that stabilized Evi5 mutants deficient in Plk1 phos-
phorylation still leave the centrosome in early mitosis when
Emi1 becomes concentrated on spindle poles. This change
in Evi5 localization in early mitosis, which separates Evi5 and
Emi1 spatially, may represent another pathway to inactivate
Evi5 in mitosis.
Coupling Evi5 Function at the Centrosome to Emi1
and Cyclin Accumulation
Evi5 localizes to the centrosome from early G1 to prophase.
We also find that a pool of Emi1 is centrosomal, suggesting
that Evi5 may stabilize Emi1 there (Figure 7). Plk2 activity has
been suggested to be required for splitting of centrioles at
the G1/S transition (Warnke et al., 2004), and the presence
of Evi5 could protect Emi1 from phosphorylation-triggered
destruction by Plk2 or another Plk at that time. It should be
noted, however, that Plk2 knockout mice are viable despite
displaying some developmental defects, and Plk2/ MEFs
are able to grow in culture, albeit at a reduced rate, suggest-
ing that Plk2 is not absolutely required for progression of
the centrosome cycle (Ma et al., 2003). Cyclin A, a known
APC/C substrate, is required for centriolar splitting at the
G1/S transition (Meraldi et al., 1999) and thus might require
Evi5 and Emi1 for its stabilization at the centriole. Later, ac-
tivation of Plk1 may displace Evi5 and Emi1 from the centro-
some to destabilize cyclin A and prevent premature splitting
of duplicated centrioles in mitosis.
Components of the SCF have also been found at the cen-
trosome (Freed et al., 1999). Notably, bTrCP1 has been
found at the centrosome, and knockout of bTrCP1 causes
centrosome overduplication in mouse embryo fibroblasts
(Guardavaccaro et al., 2003). The SCF component Skp1
and the active, neddylated form of Cul1 are highly enriched378 Cell 124, 367–380, January 27, 2006 ª2006 Elsevier Inc.at the centrosome, suggesting that an active form of the
SCF localizes there (Freed et al., 1999). The possibility of
an organized centrosomal ubiquitination/destruction factory
has been argued for the spindle-associated destruction of
cyclin B (Wakefield et al., 2000) and misfolded proteins in
aggresomes (Kopito, 2000). An interesting model posits
that Evi5-dependent stabilization of centrosomal Emi1
would primarily direct the accumulation of cyclin A at centro-
somes, as suggested above. Another possibility is that there
is a critical coupling between the centrosomal and bulk pools
of Emi1 and cyclin A, with the centrosomal destruction fac-
tory serving to drain the cellular pools of these critical regula-
tors. The ability of Evi5 to ‘‘plug’’ the drain might then couple
events at the centrosome to the accumulation of Emi1 and
cyclins. Here, Polo-like kinases would provide the critical
control to open the drain by triggering Evi5 destruction.
Evi5 Is a Member of a Family of Proteins Containing
Amino-Terminal RabGAP Domains
and Carboxy-Terminal Coiled-Coil Domains
Evi5 shares a similar RabGAP/coiled-coil domain structure
with two other proteins that are conserved from humans to
Drosophila (see Figure 1A). One of these, GAPCenA, has
also been shown to localize to centrosomes through its
coiled coil and shows GAP activity for the small GTP binding
protein Rab6 in vitro (Cuif et al., 1999). We have not yet
shown that Evi5 possesses GAP activity, but the high homol-
ogy of its GAP domain to those of GAPCenA and other Rab-
GAPs (Figure S1) suggests that it may serve as a GAP for an
unknown Rab GTPase. So far, we have not found any phe-
notypic abnormalities resulting from expression of Evi5 vari-
ants containing inactivating point mutations in their GAP do-
main (A.G.E. and P.K.J., unpublished data). We believe that
the GAP function may be distinct from the Emi1 stabilizing
activity and may relate to the interaction of Evi5 with centro-
somes or microtubules, possibly as part of a GTPase cycle.
An intriguing possibility is that an Evi5-regulated GTPase cy-
cle plays a role in regulating protein stability at the centro-
some.
Another homolog, more closely related to Evi5 than
GAPCenA, which we call Evi5 homolog (Evi5H), remains as
yet completely uncharacterized. Preliminary experiments us-
ing RNA interference directed against the uncharacterized
Evi5H show a clear difference in function between Evi5 and
its homolog; knockdown of the homolog fails to result in the
characteristic destabilization of Emi1 and cyclin A seen fol-
lowing Evi5 knockdown but does show other cell-cycle
abnormalities (A.G.E. and P.K.J., unpublished data). We
are interested in exploring the extent to which these proteins
serve similar or differing roles in the cell.
Evi5 Is a Candidate Oncogene that May Regulate
Transformation by Perturbing Emi1 and Cyclin
Accumulation, Leading to Genomic Instability
The identification of Evi5 as a potential oncogene in mice and
humans strongly suggests that Evi5 plays a role in tumori-
genesis. We have tested Evi5 for its ability to acutely trans-
form both fibroblasts and interleukin 3-dependent lymphoid
(BaF3) cells. To date, expression of Evi5 and all available mu-
tants, including the truncation isolated from a patient with
stage 4S neuroblastoma (Roberts et al., 1998), failed to
transform cells, suggesting that Evi5 is less likely to be an
acutely transforming gene. Rather, we suspect that long-
termmisregulation of Evi5 in vivo leads to genomic instability,
fostering the generation of secondary mutations in the tu-
morigenic pathway. Misregulation of Emi1 appears to play
an important role in driving mitotic catastrophe and genomic
instability in a wide variety of human cancers, including many
lymphomas, carcinomas, and neural tumors (N. Lehman
and P.K.J., unpublished data), and the interaction of Evi5
and Emi1 may point to an involvement of Evi5 in these tumor
types.
EXPERIMENTAL PROCEDURES
Cloning and Plasmid and Protein Generation
Xenopus Evi5 sequence was obtained by anchored PCR from a Xenopus
oocyte cDNA library. Percent identities of Evi5 orthologs and homologs
were determined by the Jotun Hein algorithm. Human Evi5, Plk2/3, and
variants were cloned into pCS2 myc6, pCS2 HA3, pGex 6P-1, or
pMAL-c2 as indicated. Emi1 (Hsu et al., 2002), bTrCP (Margottin-Goguet
et al., 2003), and Plk1 (Hansen et al., 2004) constructs were previously
described. GST and MBP fusions were purified by standard methods.
Xenopus Plx1 was expressed and purified from baculovirus (Hansen
et al., 2004). Cyclin B/Cdc2 kinase was from New England Biolabs. Gen-
Bank accession numbers of Evi5 family members are NM_005665
(HsEvi5), AJ011679 (HsGAPCenA), and BC014111 (HsEvi5 homolog).
Plasmid and siRNA Transfections
Plasmid transfections used Fugene 6 (Roche) according to the manufac-
turer’s protocols. siRNA duplexes from Dharmacon were transfected at
50–100 nM final concentration using oligofectamine (Invitrogen).Antibody Generation
Bacterially produced MBP-Evi5N was used to raise polyclonal antibodies
in rabbits (Josman Laboratories). Rabbit sera were subtracted against
MBP protein and affinity purified on an MBP-Evi5N column. Monoclonal
antibody against human Emi1 (clone 5G12) was from N. Lehman.
Tissue Culture and Immunofluorescence
Cells were fixed in 4% paraformaldehyde and stained as described (Hsu
et al., 2002). For centrosomal staining, cells were pre-extracted in PHEM
buffer (60 mM PIPES, 25 mMHEPES, 10 mM EGTA, 4 mMMgSO4, 0.1%
Triton X-100 [pH 7.0]). Microscopy used a Zeiss Axiovert 200M micro-
scope (Intelligent Imaging Innovations) and Slidebook4 software.
Cell Synchronizations and Flow Cytometry
Synchronizations and flow analysis were as described (Hsu et al., 2002).
For proteasome inhibition in vivo, MG-132 was used at 20 mM and epox-
omicin at 1 mM. For thymidine synchronization followed by cycloheximide
treatment, HeLa cells were treated for 21 hr with 2 mM thymidine, trans-
fected with siRNA for 21 hr, and released into fresh media containing cy-
cloheximide (20 mg/ml), and time points were harvested as indicated.
Emi1 levels were quantified using ImageQuant software.
Coimmunoprecipitations and Binding Experiments
Coimmunoprecipitations were as described (Hsu et al., 2002), using
300 mM NaCl, 0.3% Triton X-100, 50 mM b-glycerophosphate, 5 mM
EDTA, 1 mM DTT, 1% Aprotinin (pH 7.2) as wash buffer. In vitro binding
assays were as described (Hansen et al., 2004).
In Vitro Kinase Assays
0.5 mM purified substrate protein was incubated with either 40 ng His-
Plx1 or 4 units cyclin B/Cdc2 (New England Biolabs) in 50 mM Tris (pH
7.5), 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 100 mM cold ATP, and
0.25 mCi/ml [g-32P]ATP (PerkinElmer Life and Analytical Sciences, Bos-
ton). Reactions were incubated at 30ºC for 40 min and analyzed by
SDS-PAGE and autoradiography.
Destruction Assays
Destruction assays in HeLa lysate were as described (Montagnoli et al.,
1999).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures and
11 figures and can be found with this article online at http://www.cell.
com/cgi/content/full/124/2/367/DC1/.
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